【內科部 GrandRound】

日期: 113年 03月 12日   地點:B1 第一演講廳

主題: 

Update of therapy for irritable bowel disease

講者: 胃腸科 周益霆醫師

大綱:

According to Rome IV criteria, irritable bowel syndrome(IBS) is a functional gastrointestinal disease characterized by recurrent abdominal pain, discomfort, and altered bowel habits which do not present with identifiable organic lesions. The pathophysiology of IBS remained unclear, which include altered motility, enhanced visceral hypersensitivity, dysregulation in the brain-gut axis, alteration of the gut microbiome, food intolerances or hypersensitivity, post-infectious immune reactivity, and chronic intestinal inflammation. Traditional IBS therapies are symptom driven and consisted of anti-diarrheal and laxative medications for bothersome bowel habits and anti-spasmodic or pain medication for sensory symptoms. Because of the unmet need of current IBS therapy, great efforts in the development of novel pharmacotherapy have been put from many pharmaceutical companies. Recently, at least 7 new drugs have been approved for the treatment in Western countries and several Asian countries.